News & Information

August 14:  Esperance Pharmaceuticals Names Prominent Chinese Researcher and Clinician as Scientific Advisor

April 16:  Preclinical Data Presented at AACR 2018 Shows Esperance Pharmaceuticals’ EP-100 is Synergistic with PARP Inhibitor Olaparib in Ovarian Cancer

Poster Presentation:  American Association of Cancer Research (AACR) Poster #0405
“EP-100 sensitizes BRCA wild-type ovarian cancer cells to PARP inhibitor”

2017

April 10: Esperance Pharmaceuticals Names Noted Cancer Researcher Mark Pegram MD as Scientific Advisor

Publication:  Leuschner C, Coulter A, Keener J, Alila H (2017) Targeted Oncolytic Peptide for Treatment of Ovarian Cancers. Int J Cancer Res Mol Mech 3(1)

2016

March 30:  Houston Biotech Esperance Eyes $40M Raise to Fund Cancer Drug Push

March 17:  Esperance Pharmaceuticals Inc. today announced that Brett P. Giroir MD has joined the company’s Board of Directors, effective immediately.

2015

April 4:  Esperance moves offices to Houston Texas

August 24:  Esperance Announces Strategic Alliance with MD Anderson Cancer Center

June 1:  Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting

Poster Presentation:  American Society of Clinical Oncology (ASCO) #5528
“EP-100 Paclitaxel Overcomes Taxane Resistance in Patients with Recurrent LHRH Receptor Expressing Ovarian Cancer”

2014

Publication:  Curtis, K. (2014). Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first in human phase I study in patients with advanced LHRH-receptor expressing tumors. Cancer Chemother Pharmacol 73, 931-941.

2013

Poster Presentation:  American Association of Cancer Research (AACR) #978
“Synergistic Activity of EP-100 and Chemotherapies in Cancer Cell Lines”

2012

August 28: Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer

June 4: Esperance Pharmaceuticals Presents Results from Phase 1 Study of EP-100 in Advanced, Refractory LHRH-Receptor Expressing Solid Tumors at ASCO

May 17: Esperance Pharmaceuticals Initiates Phase 2 Clinical Trial of its Novel Membrane-disrupting Agent, EP-100, in Patients with Advanced Ovarian Cancer Esperance

April 3:  Pharmaceuticals Presents Poster at AACR Annual Meeting Demonstrating Synergy of Lead Candidate EP-100 with Paclitaxel in In Vitro Studies

Poster Presentation:  American Association of Cancer Research (AACR) #2829
“Activity of EP-100 in Non-Hodgkin’s Lymphoma — Synergy in Combination”

Poster Presentation:  American Association of Cancer Research (AACR) #3517
“EP-100 Synergizes with Paclitaxel in Ovarian, Breast and Prostate Cancer Cell Lines”

2011

August 8:  Esperance Pharmaceuticals Closes Series B Financing

June 1: Esperance Pharmaceuticals Completes $7.5 Million Series B Financing

Poster Presentation:  American Association of Cancer Research #204
“Pre-treatment with FSH Enhances the Ability of a LHRH-Lytic Peptide Conjugate (EP-100) to Target and Destroy Human Pancreatic Cancer Cells”

2010

April 20:   Third Candidate from Esperance’s Targeted Anti-cancer Platform, EP-302, Establishes Preclinical Proof of Concept

2009

September 10:  Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer

April 21:   First Candidate from Esperance’s Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

Poster Presentation:  American Association of Cancer Research (AACR) #4666
“Targeted Oncolytic Peptide for Treatment of Ovarian Cancers”

2008

April 24:  First Louisiana Biotech Company Focused on Cancer Announces Opening

2006

October 31:  Esperance Pharmaceuticals Closes $9 Million Series A Funding